Dr. Kochhar, M.D., is a Clinical Research & Drug Development Specialist at PATH who has extensive global experience in vaccines and drug development for infectious diseases (including HIV/AIDS). She has provided leadership for clinical development strategy, implementation, and regulatory support for Phase I – IV international trials for vaccines and drugs conducted in adult and pediatric populations in the USA, Europe, India, Africa and Asia. In her previous position as Medical Director for the International AIDS Vaccine Initiative, she provided leadership for the first AIDS vaccine trials in India.
She has also been guest faculty for international vaccinology and clinical research professional programs, a member of international groups involved in the development of a WHO globally integrated vaccine safety monitoring system, safety standards for malaria, tuberculosis and AIDS vaccine trials, on the Harvard University Multi-Regional Clinical Trial Steering Committee, the Global Health Clinical Consortium Leadership Group set up by the Gates Foundation and the Vienna Vaccine Safety Initiative working on global clinical research and safety. Kochhar serves on several international scientific advisory boards, has published numerous scientific papers, and has written book chapters on vaccine and drug development. She works with government partners for national policy and program development, including for care and treatment guidelines for trial participants.
Dr. Moran has over 20 years’ experience in health policy and practice, including 10 years specialising in neglected disease policy. She has conducted projects for a wide range of public and multilateral health organisations with a focus on policy solutions for emerging issues related to neglected disease R&D. In 2004, Mary founded the research group that became Policy Cures at the London School of Economics & Political Science, later transferring it to the George Institute for Global Health in Sydney.
Prior to forming the group, she worked for over a decade in Emergency Medicine; was a diplomat and policy analyst with the Australian Department of Foreign Affairs & Trade; Director of Medecins Sans Frontieres Access to Essential Medicines Campaign in Australia; and a Europe-based policy advocate with MSF on issues relating to access to medicines for neglected patients. Mary is an Honorary Senior Lecturer at the London School of Hygiene and Tropical Medicine, and an expert adviser to the World Health Organisation, European Commission, European and Developing Countries Clinical Trials Partnership, Global Alliance for Vaccines and Immunisation (GAVI), OECD and the Wellcome Trust.
Carl F. Nathan
Dr. Nathan is the R. A. Rees Pritchett Professor of Microbiology and Chair of the Department of Microbiology and Immunology at the Joan and Sanford I. Weill Medical College at Cornell University. Previously, he served as Acting Dean of Weill Medical College, Senior Associate Dean for Research, Director of the Tri-Institutional MD-PhD Program, and Co-Chairman of the Department of Cell Biology and Genetics Program at Weill Graduate School of Medical Sciences. He was also the Stanton Griffis Distinguished Professor of Medicine in the Department of Medicine at Weill Medical College.
Dr. Nathan is the author or co-author of more than 150 scientific articles and more than 60 monographs, book chapters, and reviews. He has served as an editor of the Journal of Experimental Medicine since 1988, and also has editorial responsibilities for the Journal of Clinical Investigation and the journal Molecular Medicine. He was recently honored with election to the National Academy of Sciences, Institute of Medicine.
Dr. Nathan received his Bachelor of Arts degree summa cum laude from Harvard College in 1967 and graduated magna cum laude from Harvard Medical School in 1972 with a concentration in immunology. He completed his post-graduate training at Massachusetts General Hospital in 1974 and joined the faculty of The Rockefeller University in 1977.
Mark V. Pauly
Mark V. Pauly is Bendheim Professor in the Department of Health Care Management, Professor of Health Care Management, Insurance and Risk Management, and Business and Public Policy at The Wharton School. He is also Co-Director of the Roy and Diana Vagelos Life Sciences and Management Program, and Professor of Economics in the School of Arts and Sciences at the University of Pennsylvania. A former commissioner on the Physician Payment Review Commission, Dr. Pauly has served on the advisory committee to the Agency for Health Care Research and Quality, and on the Medicare Technical Advisory Panel. He currently serves on the National Advisory Council for the National Institutes of Health National Center for Research Resources, the National Academy of Sciences’ Committee to Study the Veterinary Workforce, and the NAS Committee on the Biomedical Workforce. He has been a consultant to the Congressional Budget Office, the Office of the Secretary of the U.S. Department of Health and Human Services (which supported some of his work on individual health insurance), and health trade associations. Dr. Pauly is a co-editor-in-chief of the International Journal of Health Care Finance and Economics and an associate editor of the Journal of Risk and Uncertainty.
Dorairaj Prabhakaran, a cardiologist and epidemiologist by training, is the Executive Director of the Centre for Chronic Disease Control (CCDC). Until September 2007, he was Additional Professor of Cardiology at the All India Institute of Medical Sciences (AIIMS), New Delhi. In 2011, he was elected as a Fellow of the Royal College of Physicians ( London). He has been involved in several major international and national research studies including the INTERHEART Study, the CREATE Trial, Indian Council of Medical Research commissioned national case-control study on Acute myocardial infarction, British Heart Foundation funded projects on low birth weight and migrunded impact of intra-country migration on CHD, the NIH sponsored STICH trial and the India Health Study. He has recently been awarded the prestigious NHLBI-Ovations Grant and is a co-investigator for the Fogarty International-funded capacity building project. He is also Professor of Chronic Disease Epidemiology at the Public Health Foundation of India and Deputy Director of the South Asia center for Chronic Diseases Funded by the Wellcome Trust.
He is a member of the Scientific Council of the Section on Epidemiology and Prevention of the World Heart Federation, Cardiological Society of India, Association of Physicians of India, Indian Council of Medical Research’s Project Review Committee on Cardiology and Indian Council of Medical Research’s Advisory Committee on Hypertension. Along with more than 150 publications, he is also on the review board and is a referee for various journals, a reviewer for various research funding agencies, and Co-Editor of Global Heart.
Harvey Rubin, Chair
Dr. Rubin is Professor of Medicine at University of Pennsylvania with secondary appointments in the Departments of Microbiology, Biochemistry and Computer and Information Sciences. He is the Chair of the Scientific Advisory Board for the Incentives for Global Health and Director of Penn’s Institute for Strategic Threat Analysis and Response (ISTAR). He received his Ph.D. in Molecular Biology from the University of Pennsylvania in 1974 and his M.D. from Columbia University in 1976. Previously, he was a House Officer in Medicine at The Peter Bent Brigham Hospital in Boston and did his fellowship in infectious diseases at Harvard and the Brigham. His research on the basic biology of tuberculosis and the mathematical modeling of complex biological systems has been funded by the NIH, NSF, DARPA and the Global Alliance for TB Drug Discovery. He has published over 90 papers in peer reviewed journals as well as numerous scientific reviews and book chapters.
Dr. Rubin served on various scientific review panels including those for the NIH, NSF, NASA Intelligent Systems Program, DARPA, and The Medical Research Council, South Africa. He was a member of the United States National Science Advisory Board for Biosecurity (NSABB) and the Department of Defense/National Academy of Sciences Biological Cooperative Threat Reduction Program.
Joshua Salomon is Associate Professor of International Health in the Department of Global Health and Population at Harvard School of Public Health. His research focuses on priority-setting in global health, within three main substantive areas: 1) measurement and valuation of population health; 2) modeling of patterns and trends in major causes of global mortality and disease burden; and 3) evaluation of health policies and interventions. Prof. Salomon is an investigator on projects funded by NIH and the Gates Foundation relating to comparability of health measures; the global burden of disease; modeling of infectious and chronic diseases and interventions; and evaluating the potential impact and cost effectiveness of new health technologies. Professor Salomon received his PhD in Health Policy and Decision Science from Harvard University.
Dr. Spigelman is the President and Chief Executive Officer of the Global Alliance for TB Drug Development (TB Alliance). He also serves on the Coordinating Board of the WHO Stop TB Partnership, is Co-chair of the Working Group on New Drugs of the WHO Stop TB Partnership, and is a member of the Governing Board of the Tres Cantos Open Lab, GlaxoSmithKline.
Previously, Dr. Spigelman served for five and a half years as the Director of Research and Development at the TB Alliance. A highly regarded expert in domestic and international drug research and development, Dr. Spigelman previously spent a decade managing drug R&D at Knoll Pharmaceuticals (a division of BASF Pharma). As Vice President of R&D at Knoll for eight years, he directed clinical development and supervised all R&D activities from basic discovery to regulatory approval and Medical Affairs. He established global R&D processes as part of Knoll’s senior R&D management team, oversaw a marked increase in US regulatory filings and approvals, and supervised joint R&D programs with multiple other pharmaceutical companies.
Dr. Spigelman received his undergraduate degree from Brown University and his medical degree from the Mt. Sinai School of Medicine where he specialized in Internal medicine, Neoplastic Diseases and Preventive Medicine. Dr. Spigelman holds board certifications from the American Board of Internal Medicine, the American Board’s Subspecialty Board of Medical Oncology, and the American Board of Preventive Medicine and was the recipient of the American Cancer Society Clinical Oncology Career Development Award (1985-1988).
Wu Qunhong is the Executive Dean of Health Management College and the Director of Health Policy and Management Research Center at Harbin Medical University. She has worked as a policy advisor to the WHO China of?ce, and has been involved in projects at the World Bank, DFID, and the Australian Agency for International Development. At the Ministry of Health, she has consulted in various areas of health systems and policy. A prolific writer, she has published many books such as Health Policy in Transition: Challenge for China; Medical Demography; Consumer Oriented Hospital Marketing; Dancing with the Crisis-Strategies of Copying with Public Health Emergencies; Case Studies on Public Health Emergency Response and its Revelation to Modern Society; Social Medicine; Health Project Evaluation, Economics on the Reimbursement for Health Services Provider; and over 100 academic papers. She was awarded the Excellent Young Scientist Award of Ministry of Health in 2008m Excellent Researcher of China in 2012, and the Distinguished Professor Award of CMB. She has also been Vice President of Chinese Association of Public Health Emergency Management, Standing Director of Health Management Association of China, as well as Standing Director of Social Medicine Association of China, amongst many other endeavours.